Abstract
Background
Restless legs syndrome (RLS) is characterized by an unpleasant or painful sensation generally localized to lower limbs and relieved by movement. Its pathogenesis is hypothesized to involve the dopaminergic system, also in the light of the response of RLS to ex adiuvantibus treatment with dopamine agonists. DNAJC12 deficiency is a recently identified inherited metabolic disease coupling hyperphenylalaninemia to deficient dopaminergic and serotoninergic neurotransmission, due to the combined impairment of the three aromatic amino acids’ (i.e., phenylalanine, tyrosine, and tryptophan) hydroxylases. DNAJC12 deficiency was reported in 43 patients so far, presenting with wide spectrum of clinical symptoms.
Case presentation results
Here, we report RLS as a novel clinical manifestation of DNAJC12 deficiency, occurring in two adults while on treatment with l-dopa at longitudinal follow-up. The adjunct of low-dose pramipexole was effective in both patients to treat RLS. Besides, this treatment also allowed an improvement of dopaminergic homeostasis, as evidenced by clinical amelioration and stabilization of a peripheral short prolactin profile (a tool to indirectly evaluate dopaminergic homeostasis).
Discussion
Besides including RLS as a new treatable clinical manifestation of DNAJC12, these observations may suggest the opportunity of a selective screening for DNAJC12 deficiency in patients with idiopathic RLS.
This is a preview of subscription content, log in via an institution to check access.
Data availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Code availability
Not applicable.
References
Klingelhoefer L, Bhattacharya K, Reichmann H (2016) Restless legs syndrome. Clin Med (Lond) 16:379–382
Gonzalez-Latapi P, Malkani R (2019) Update on Restless Legs Syndrome: from Mechanisms to Treatment. Curr Neurol Neurosci Rep 19:54
Tipton P, Wszolek Z (2017) Restless legs syndrome and nocturnal leg cramps: a review and guide to diagnosis and treatment. Pol Arch Intern Med 127:865–872
Anikster Y, Haack TB, Vilboux T, Pode-Shakked B, Thöny B, Shen N, Guarani V, Meissner T, Mayatepek E, Trefz FK, Marek-Yagel D, Martinez A, Huttlin EL, Paulo JA, Berutti R, Benoist JF, Imbard A, Dorboz I, Heimer G, Landau Y, Ziv-Strasser L, Malicdan MCV, Gemperle-Britschgi C, Cremer K, Engels H, Meili D, Keller I, Bruggmann R, Strom TM, Meitinger T, Mullikin JC, Schwartz G, Ben-Zeev B, Gahl WA, Harper JW, Blau N, Hoffmann GF, Prokisch H, Opladen T, Schiff M (2017) Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet 100:257–266
Straniero L, Guella I, Cilia R, Parkkinen L, Rimoldi V, Young A, Asselta R, Soldà G, Sossi V, Stoessl AJ, Priori A, Nishioka K, Hattori N, Follett J, Rajput A, Blau N, Pezzoli G, Farrer MJ, Goldwurm S, Rajput AH, Duga S (2017) DNAJC12 and dopa-responsive nonprogressive parkinsonism. Ann Neurol 82:640–646
Porta F, Ponzone A, Spada M (2015) Short prolactin profile for monitoring treatment in BH4 deficiency. Eur J Paediatr Neurol 19:360–363
Porta F, Ponzone A, Spada M (2016) Target prolactin range in treatment of tetrahydrobiopterin deficiency. J Pediatr 168:236-239.e1
de Sain-van der Velden MGM, Kuper WFE, Kuijper MA, van Kats LAT, Prinsen HCMT, Balemans ACJ, Visser G, van Gassen KLI, van Hasselt PM (2018) Beneficial effect of BH4 treatment in a 15-year-old boy with biallelic mutations in DNAJC12. JIMD Rep 42:99-103
van Spronsen FJ, Himmelreich N, Rüfenacht V, Shen N, Vliet DV, Al-Owain M, Ramzan K, Alkhalifi SM, Lunsing RJ, Heiner-Fokkema RM, Rassi A, Gemperle-Britschgi C, Hoffmann GF, Blau N, Thöny B (2017) Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: from attention deficit to severe dystonia and intellectual disability. J Med Genet 2017:104875
Veenma D, Cordeiro D, Sondheimer N, Mercimek-Andrews S (2018) DNAJC12-associated developmental delay, movement disorder, and mild hyperphenylalaninemia identified by whole-exome sequencing re-analysis. Eur J Hum Genet 26:1867–1870
Feng Y, Liu S, Tang C, Jiang X, Tang F, Li B, Jia X, Chen Q, Liu J, Huang Y (2019) Identification of an inherited pathogenic DNAJC12 variant in a patient with hyperphenylalalinemia. Clin Chim Acta 490:172–175
Gallego D, Leal F, Gámez A, Castro M, Navarrete R, Sanchez-Lijarcio O, Vitoria I, Bueno-Delgado M, Belanger-Quintana A, Morais A, Pedrón-Giner C, García I, Campistol J, Artuch R, Alcaide C, Cornejo V, Gil D, Yahyaoui R, Desviat LR, Ugarte M, Martínez A, Pérez B (2020) Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. Hum Mutat 41:1329–1338
Li M, Yang Q, Yi S, Qin Z, Luo J, Fan X (2020) Two novel mutations in DNAJC12 identified by whole-exome sequencing in a patient with mild hyperphenylalaninemia. Mol Genet Genomic Med 8:e1303
Çıkı K, Yıldız Y, Yücel Yılmaz D, Pektaş E, Tokatlı A, Özgül RK, Sivri HS, Dursun A (2021) DNACJ12 deficiency in patients with unexplained hyperphenylalaninemia: two new patients and a novel variant. Metab Brain Dis 36:1405–1410
Porta F, Ponzone A, Spada M (2020) Phenylalanine and tyrosine metabolism in DNAJC12 deficiency: a comparison between inherited hyperphenylalaninemias and healthy subjects. Eur J Paediatr Neurol 28:77–80
KuseyriHübschmann O, Horvath G, Cortès-Saladelafont E, Yıldız Y, Mastrangelo M, Pons R, Friedman J, Mercimek-Andrews S, Wong SN, Pearson TS, Zafeiriou DI, Kulhánek J, Kurian MA, López-Laso E, Oppebøen M, Kılavuz S, Wassenberg T, Goez H, Scholl-Bürgi S, Porta F, Honzík T, Santer R, Burlina A, Sivri HS, Leuzzi V, Hoffmann GF, Jeltsch K, Hübschmann D, Garbade SF, iNTD Registry Study Group, García-Cazorla A, Opladen T (2021) Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nat Commun 12:5529
Porta F, Mussa A, Concolino D, Spada M, Ponzone A (2009) Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 73:633–637
Porta F, Mussa A, Concolino D, Spada M, Ponzone A (2012) Dopamine agonists in dihydropteridine reductase deficiency. Mol Genet Metab 105:582–584
Opladen T, López-Laso E, Cortès-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, Assmann B, Kurian MA, Leuzzi V, Heales S, Pope S, Porta F, García-Cazorla A, Honzík T, Pons R, Regal L, Goez H, Artuch R, Hoffmann GF, Horvath G, Thöny B, Scholl-Bürgi S, Burlina A, Verbeek MM, Mastrangelo M, Friedman J, Wassenberg T, Jeltsch K, Kulhánek J, KuseyriHübschmann O, International Working Group on Neurotransmitter related Disorders (iNTD) (2020) Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis 15:126
Porta F, Ponzone A, Spada M (2016) Long-term safety and effectiveness of pramipexole in tetrahydrobiopterin deficiency. Eur J Paediatr Neurol 20:839–842
Author information
Authors and Affiliations
Contributions
FP: acquisition, analysis, and interpretation of data, drafted and revised the work, approved the version to be published, agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
AN, MS: acquisition of data, revised the work, approved the version to be published, agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Corresponding author
Ethics declarations
Ethical approval
None.
Conflict of interest
The authors declare no competing interests.
Informed consent
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Porta, F., Neirotti, A. & Spada, M. Restless legs syndrome in DNAJC12 deficiency. Neurol Sci 44, 2167–2172 (2023). https://doi.org/10.1007/s10072-023-06733-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06733-9